<DOC>
	<DOCNO>NCT01692678</DOCNO>
	<brief_summary>The purpose study find optimal dose trabectedin Chinese patient locally advanced metastatic L-sarcoma ( liposarcoma leiomyosarcoma ) previously treat ( order ) least anthracycline ifosfamide contain regimen , anthracycline contain regimen 1 additional cytotoxic chemotherapy regimen ( Part 1 ) evaluate whether overall survival ( OS ) trabectedin group superior dacarbazine group ( Part 2 ) .</brief_summary>
	<brief_title>A Study Trabectedin ( YONDELIS ) Patients With Locally Advanced Metastatic Liposarcoma Leiomyosarcoma</brief_title>
	<detailed_description>The study divide 2 separate part ( ie , Part 1 Part 2 ) . Part 1 dose find part ( find optimal dose ) trabectedin Chinese patient , Part 2 multicenter , randomize ( study medication assign chance ) , active-controlled ( active substance compare study medication test whether study medication real effect clinical study ) , parallel-group ( study compare response two group patient receive different intervention ) , open-label ( people know identity intervention ) bridge part compare efficacy safety optimal dose trabectedin dacarbazine population Part 1 . The study ( Part 1 Part 2 ) consist screen phase , treatment phase follow-up phase . Part 1 : Optimal dose ( ie , maximum tolerate dose [ MTD ] ) determine follow 3 dose level : Dose level 1 ( 1.5 mg/m2 ) , Dose level 2 ( 1.2 mg/m2 ) , Dose level 3 ( 1.0 mg/m2 ) trabectedin . Cohorts 6 patient treat dose level . To determine MTD , dose limit toxicity ( DLT ; pre-defined adverse event occur first cycle ie , Cycle 1 ) determine . In first cohort 6 patient , ( ) DLT le equal 1 dose level , consider MTD ( b ) DLT great 2 , patient de-escalated next dose level ( c ) DLT equal 2 , 3 patient include dose level DLT 3 patient , dose level consider MTD . Part 2 : If optimal dose find Part 1 1.5 mg/m2 , approximately 48 patient randomly assign either trabectedin ( approximately 32 patient ) dacarbazine ( approximately 16 patient ) treatment group Part 2 . If optimal dose find Part 1 1.5 mg/m2 , 123 patient randomly assign either trabectedin ( approximately 82 patient ) dacarbazine ( approximately 41 patient ) treatment group . Safety evaluate assess adverse event , clinical laboratory test , multiple gated acquisition scan , electrocardiogram , vital sign , physical examination throughout study 30 day end treatment .</detailed_description>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Histologically proven , unresectable , locally advanced metastatic liposarcoma leiomyosarcoma Treated order least : anthracycline ifosfamide contain regimen , anthracycline contain regimen 1 additional cytotoxic chemotherapy regimen Measurable disease baseline accordance Response Evaluation Criteria Solid Tumors ( RECIST ) criterion Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Adequate recovery prior therapy ; side effect ( except alopecia ) resolve Grade 1 less accord National Cancer Institute Adequate organ function hepatic function Prior exposure trabectedin ( Part 1 Part 2 ) dacarbazine ( Only Part 2 ) Less 3 week last dose systemic cytotoxic therapy , radiation therapy , therapy investigational agent Other malignancy within past 3 year ( exception : basal nonmetastatic squamous cell carcinoma skin , cervical carcinoma situ , Federation Internationale de Gynecologie et d'Obstetrique ( FIGO ) Stage 1 carcinoma cervix ) Known central nervous system metastasis Active symptomatic viral hepatitis chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced Metastatic liposarcoma leiomyosarcoma</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>L-sarcoma</keyword>
	<keyword>Liposarcoma</keyword>
	<keyword>Leiomyosarcoma</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>Yondelis</keyword>
	<keyword>Chinese patient</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>